{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T23:21:03Z","timestamp":1788823263436,"version":"build-2803163510"},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2016,4,4]],"date-time":"2016-04-04T00:00:00Z","timestamp":1459728000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Ann Hematol"],"published-print":{"date-parts":[[2016,5]]},"DOI":"10.1007\/s00277-016-2650-x","type":"journal-article","created":{"date-parts":[[2016,4,4]],"date-time":"2016-04-04T03:24:29Z","timestamp":1459740269000},"page":"945-957","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Distinct mechanisms account for acquired von Willebrand syndrome in plasma cell dyscrasias"],"prefix":"10.1007","volume":"95","author":[{"given":"Christina","family":"Dicke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sonja","family":"Schneppenheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharina","family":"Holstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brigitte","family":"Spath","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carsten","family":"Bokemeyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rita","family":"Dittmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ulrich","family":"Budde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Florian","family":"Langer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,4,4]]},"reference":[{"issue":"Suppl 2","key":"2650_CR1","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S0049-3848(13)70003-3","volume":"130","author":"A Tiede","year":"2012","unstructured":"Tiede A (2012) Diagnosis and treatment of acquired von Willebrand syndrome. Thromb Res 130(Suppl 2):S2\u2013S6. doi: 10.1016\/S0049-3848(13)70003-3","journal-title":"Thromb Res"},{"issue":"8","key":"2650_CR2","doi-asserted-by":"crossref","first-page":"616","DOI":"10.1002\/ajh.20455","volume":"81","author":"H Mohri","year":"2006","unstructured":"Mohri H (2006) Acquired von Willebrand syndrome: features and management. Am J Hematol 81(8):616\u2013623. doi: 10.1002\/ajh.20455","journal-title":"Am J Hematol"},{"issue":"2","key":"2650_CR3","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1053\/beha.2001.0141","volume":"14","author":"JJ Michiels","year":"2001","unstructured":"Michiels JJ, Budde U, van der Planken M, van Vliet HH, Schroyens W, Berneman Z (2001) Acquired von Willebrand syndromes: clinical features, aetiology, pathophysiology, classification and management. Best Pract Res Clin Haematol 14(2):401\u2013436. doi: 10.1053\/beha.2001.0141","journal-title":"Best Pract Res Clin Haematol"},{"issue":"2","key":"2650_CR4","first-page":"345","volume":"84","author":"AB Federici","year":"2000","unstructured":"Federici AB, Rand JH, Bucciarelli P, Budde U, van Genderen PJ, Mohri H, Meyer D, Rodeghiero F, Sadler JE, Subcommittee on von Willebrand F (2000) Acquired von Willebrand syndrome: data from an international registry. Thromb Haemost 84(2):345\u2013349","journal-title":"Thromb Haemost"},{"issue":"5","key":"2650_CR5","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1111\/j.1538-7836.2008.02945.x","volume":"6","author":"U Budde","year":"2008","unstructured":"Budde U, Schneppenheim R, Eikenboom J, Goodeve A, Will K, Drewke E, Castaman G, Rodeghiero F, Federici AB, Batlle J, Perez A, Meyer D, Mazurier C, Goudemand J, Ingerslev J, Habart D, Vorlova Z, Holmberg L, Lethagen S, Pasi J, Hill F, Peake I (2008) Detailed von Willebrand factor multimer analysis in patients with von Willebrand disease in the European study, molecular and clinical markers for the diagnosis and management of type 1 von Willebrand disease (MCMDM-1VWD). J Thromb Haemost 6(5):762\u2013771. doi: 10.1111\/j.1538-7836.2008.02945.x","journal-title":"J Thromb Haemost"},{"key":"2650_CR6","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/2162-3619-3-21","volume":"3","author":"C Dicke","year":"2014","unstructured":"Dicke C, Holstein K, Schneppenheim S, Dittmer R, Schneppenheim R, Bokemeyer C, Iking-Konert C, Budde U, Langer F (2014) Acquired hemophilia A and von Willebrand syndrome in a patient with late-onset systemic lupus erythematosus. Exp Hematol Oncol 3:21. doi: 10.1186\/2162-3619-3-21","journal-title":"Exp Hematol Oncol"},{"issue":"1","key":"2650_CR7","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3109\/09537104.2011.590255","volume":"23","author":"B Spath","year":"2012","unstructured":"Spath B, Hansen A, Bokemeyer C, Langer F (2012) Succinate reverses in-vitro platelet inhibition by acetylsalicylic acid and P2Y receptor antagonists. Platelets 23(1):60\u201368. doi: 10.3109\/09537104.2011.590255","journal-title":"Platelets"},{"issue":"5","key":"2650_CR8","doi-asserted-by":"crossref","first-page":"396","DOI":"10.1002\/ajh.21692","volume":"85","author":"M Ojeda-Uribe","year":"2010","unstructured":"Ojeda-Uribe M, Caron C, Itzhar-Baikian N, Debliquis A (2010) Bortezomib effectiveness in one patient with acquired von Willebrand syndrome associated to monoclonal gammopathy of undetermined significance. Am J Hematol 85(5):396. doi: 10.1002\/ajh.21692","journal-title":"Am J Hematol"},{"issue":"6","key":"2650_CR9","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1055\/s-2006-949663","volume":"32","author":"JJ Michiels","year":"2006","unstructured":"Michiels JJ, Berneman Z, Gadisseur A, van der Planken M, Schroyens W, Budde U, van Vliet HH (2006) Immune-mediated etiology of acquired von Willebrand syndrome in systemic lupus erythematosus and in benign monoclonal gammopathy: therapeutic implications. Semin Thromb Hemost 32(6):577\u2013588. doi: 10.1055\/s-2006-949663","journal-title":"Semin Thromb Hemost"},{"issue":"8","key":"2650_CR10","doi-asserted-by":"crossref","first-page":"2707","DOI":"10.1182\/blood.V92.8.2707","volume":"92","author":"AB Federici","year":"1998","unstructured":"Federici AB, Stabile F, Castaman G, Canciani MT, Mannucci PM (1998) Treatment of acquired von Willebrand syndrome in patients with monoclonal gammopathy of uncertain significance: comparison of three different therapeutic approaches. Blood 92(8):2707\u20132711","journal-title":"Blood"},{"issue":"3","key":"2650_CR11","doi-asserted-by":"crossref","first-page":"e188","DOI":"10.1111\/j.1365-2516.2012.02769.x","volume":"18","author":"MP Colella","year":"2012","unstructured":"Colella MP, Duarte GC, Marques JF Jr, De Paula EV (2012) Haemostatic management of extreme challenges to haemostasis in acquired von Willebrand syndrome. Haemophilia 18(3):e188\u2013e191. doi: 10.1111\/j.1365-2516.2012.02769.x","journal-title":"Haemophilia"},{"issue":"5","key":"2650_CR12","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1055\/s-0037-1615752","volume":"85","author":"J Luboshitz","year":"2001","unstructured":"Luboshitz J, Lubetsky A, Schliamser L, Kotler A, Tamarin I, Inbal A (2001) Pharmacokinetic studies with FVIII\/von Willebrand factor concentrate can be a diagnostic tool to distinguish between subgroups of patients with acquired von Willebrand syndrome. Thromb Haemost 85(5):806\u2013809","journal-title":"Thromb Haemost"},{"issue":"1","key":"2650_CR13","doi-asserted-by":"crossref","first-page":"83","DOI":"10.7326\/0003-4819-141-1-200407060-00037","volume":"141","author":"N Agarwal","year":"2004","unstructured":"Agarwal N, Klix MM, Burns CP (2004) Successful management with intravenous immunoglobulins of acquired von Willebrand disease associated with monoclonal gammopathy of undetermined significance. Ann Intern Med 141(1):83\u201384","journal-title":"Ann Intern Med"},{"issue":"10","key":"2650_CR14","doi-asserted-by":"crossref","first-page":"3623","DOI":"10.1182\/blood.V91.10.3623","volume":"91","author":"H Mohri","year":"1998","unstructured":"Mohri H, Motomura S, Kanamori H, Matsuzaki M, Watanabe S, Maruta A, Kodama F, Okubo T (1998) Clinical significance of inhibitors in acquired von Willebrand syndrome. Blood 91(10):3623\u20133629","journal-title":"Blood"},{"issue":"2","key":"2650_CR15","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1002\/(SICI)1096-8652(199702)54:2<139::AID-AJH7>3.0.CO;2-Y","volume":"54","author":"MR Rinder","year":"1997","unstructured":"Rinder MR, Richard RE, Rinder HM (1997) Acquired von Willebrand\u2019s disease: a concise review. Am J Hematol 54(2):139\u2013145","journal-title":"Am J Hematol"},{"issue":"3","key":"2650_CR16","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1182\/blood.V64.3.614.614","volume":"64","author":"PM Mannucci","year":"1984","unstructured":"Mannucci PM, Lombardi R, Bader R, Horellou MH, Finazzi G, Besana C, Conard J, Samama M (1984) Studies of the pathophysiology of acquired von Willebrand\u2019s disease in seven patients with lymphoproliferative disorders or benign monoclonal gammopathies. Blood 64(3):614\u2013621","journal-title":"Blood"},{"issue":"7","key":"2650_CR17","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1182\/blood-2007-11-122945","volume":"111","author":"L Gallinaro","year":"2008","unstructured":"Gallinaro L, Cattini MG, Sztukowska M, Padrini R, Sartorello F, Pontara E, Bertomoro A, Daidone V, Pagnan A, Casonato A (2008) A shorter von Willebrand factor survival in O blood group subjects explains how ABO determinants influence plasma von Willebrand factor. Blood 111(7):3540\u20133545. doi: 10.1182\/blood-2007-11-122945","journal-title":"Blood"},{"key":"2650_CR18","unstructured":"Budde U, Rausch T, El-Abd M\u00fcller H, Langer F, Obser T, Schneppenheim S, Dittmer R, Schneppenheim R (2014) Development of a new ELISA test for the detection of auf auto- and alloantibodies in patients with von Willebrand disease. Paper presented at the 58th Annual Meeting of the Society of Thrombosis and Haemostasis Research, Vienna, Austria"},{"issue":"2","key":"2650_CR19","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/ajh.2830350210","volume":"35","author":"C Richard","year":"1990","unstructured":"Richard C, Cuadrado MA, Prieto M, Batlle J, Lopez Fernandez MF, Rodriguez Salazar ML, Bello C, Recio M, Santoro T, Gomez Casares MT et al (1990) Acquired von Willebrand disease in multiple myeloma secondary to absorption of von Willebrand factor by plasma cells. Am J Hematol 35(2):114\u2013117","journal-title":"Am J Hematol"},{"issue":"2","key":"2650_CR20","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1055\/s-2002-27824","volume":"28","author":"U Budde","year":"2002","unstructured":"Budde U, Bergmann F, Michiels JJ (2002) Acquired von Willebrand syndrome: experience from 2 years in a single laboratory compared with data from the literature and an international registry. Semin Thromb Hemost 28(2):227\u2013238. doi: 10.1055\/s-2002-27824","journal-title":"Semin Thromb Hemost"},{"issue":"6","key":"2650_CR21","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1111\/j.1538-7836.2007.02457.x","volume":"5","author":"B Bouma","year":"2007","unstructured":"Bouma B, Maas C, Hazenberg BP, Lokhorst HM, Gebbink MF (2007) Increased plasmin-alpha2-antiplasmin levels indicate activation of the fibrinolytic system in systemic amyloidoses. J Thromb Haemost 5(6):1139\u20131142. doi: 10.1111\/j.1538-7836.2007.02457.x","journal-title":"J Thromb Haemost"},{"issue":"5","key":"2650_CR22","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1002\/ajh.20829","volume":"82","author":"CA Kos","year":"2007","unstructured":"Kos CA, Ward JE, Malek K, Sanchorawala V, Wright DG, O\u2019Hara C, Connors L, Skinner M, Seldin DC (2007) Association of acquired von Willebrand syndrome with AL amyloidosis. Am J Hematol 82(5):363\u2013367. doi: 10.1002\/ajh.20829","journal-title":"Am J Hematol"},{"issue":"2","key":"2650_CR23","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1002\/ajh.2830230210","volume":"23","author":"H Takahashi","year":"1986","unstructured":"Takahashi H, Koike T, Yoshida N, Kitahara O, Hanano M, Shibata A, Aoki N (1986) Excessive fibrinolysis in suspected amyloidosis: demonstration of plasmin-alpha 2-plasmin inhibitor complex and von Willebrand factor fragment in plasma. Am J Hematol 23(2):153\u2013166","journal-title":"Am J Hematol"},{"issue":"4","key":"2650_CR24","doi-asserted-by":"crossref","first-page":"618","DOI":"10.1111\/j.1365-2141.1992.tb03005.x","volume":"81","author":"JC Eikenboom","year":"1992","unstructured":"Eikenboom JC, van der Meer FJ, Briet E (1992) Acquired von Willebrand\u2019s disease due to excessive fibrinolysis. Br J Haematol 81(4):618\u2013620","journal-title":"Br J Haematol"},{"issue":"1","key":"2650_CR25","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1182\/blood.V79.1.38.38","volume":"79","author":"AB Federici","year":"1992","unstructured":"Federici AB, Berkowitz SD, Zimmerman TS, Mannucci PM (1992) Proteolysis of von Willebrand factor after thrombolytic therapy in patients with acute myocardial infarction. Blood 79(1):38\u201344","journal-title":"Blood"},{"issue":"1","key":"2650_CR26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/1040-8428(96)00206-5","volume":"24","author":"WL Chandler","year":"1996","unstructured":"Chandler WL (1996) The human fibrinolytic system. Crit Rev Oncol Hematol 24(1):27\u201345","journal-title":"Crit Rev Oncol Hematol"},{"issue":"3","key":"2650_CR27","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1111\/j.1365-2141.2005.05444.x","volume":"129","author":"G Cesarman-Maus","year":"2005","unstructured":"Cesarman-Maus G, Hajjar KA (2005) Molecular mechanisms of fibrinolysis. Br J Haematol 129(3):307\u2013321. doi: 10.1111\/j.1365-2141.2005.05444.x","journal-title":"Br J Haematol"},{"issue":"4","key":"2650_CR28","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1016\/j.biocel.2006.10.008","volume":"39","author":"MP Crippa","year":"2007","unstructured":"Crippa MP (2007) Urokinase-type plasminogen activator. Int J Biochem Cell Biol 39(4):690\u2013694. doi: 10.1016\/j.biocel.2006.10.008","journal-title":"Int J Biochem Cell Biol"},{"issue":"1","key":"2650_CR29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.2174\/1381612043453559","volume":"10","author":"MJ Duffy","year":"2004","unstructured":"Duffy MJ (2004) The urokinase plasminogen activator system: role in malignancy. Curr Pharm Des 10(1):39\u201349","journal-title":"Curr Pharm Des"},{"issue":"2","key":"2650_CR30","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1080\/13506120902879269","volume":"16","author":"M Uchiba","year":"2009","unstructured":"Uchiba M, Imamura T, Hata H, Tatetsu H, Yonemura Y, Ueda M, Wada Y, Mitsuya H, Ando Y (2009) Excessive fibrinolysis in AL-amyloidosis is induced by urokinae-type plasminogen activator from bone marrow plasma cells. Amyloid 16(2):89\u201393. doi: 10.1080\/13506120902879269","journal-title":"Amyloid"},{"issue":"1","key":"2650_CR31","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/0049-3848(84)90315-3","volume":"35","author":"F Wisloff","year":"1984","unstructured":"Wisloff F, Michaelsen TE, Godal HC (1984) Inhibition or acceleration of fibrin polymerization by monoclonal immunoglobulins and immunoglobulin fragments. Thromb Res 35(1):81\u201390","journal-title":"Thromb Res"},{"issue":"3","key":"2650_CR32","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1097\/MBC.0000000000000065","volume":"25","author":"M Stockschlaeder","year":"2014","unstructured":"Stockschlaeder M, Schneppenheim R, Budde U (2014) Update on von Willebrand factor multimers: focus on high-molecular-weight multimers and their role in hemostasis. Blood Coagul Fibrinolysis 25(3):206\u2013216. doi: 10.1097\/MBC.0000000000000065","journal-title":"Blood Coagul Fibrinolysis"},{"issue":"1","key":"2650_CR33","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1182\/blood.V97.1.162","volume":"97","author":"JF Dong","year":"2001","unstructured":"Dong JF, Berndt MC, Schade A, McIntire LV, Andrews RK, Lopez JA (2001) Ristocetin-dependent, but not botrocetin-dependent, binding of von Willebrand factor to the platelet glycoprotein Ib-IX-V complex correlates with shear-dependent interactions. Blood 97(1):162\u2013168","journal-title":"Blood"},{"issue":"5","key":"2650_CR34","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1160\/TH04-03-0193","volume":"93","author":"A Shinagawa","year":"2005","unstructured":"Shinagawa A, Kojima H, Berndt MC, Kaneko S, Suzukawa K, Hasegawa Y, Shigeta O, Nagasawa T (2005) Characterization of a myeloma patient with a life-threatening hemorrhagic diathesis: presence of a lambda dimer protein inhibiting shear-induced platelet aggregation by binding to the A1 domain of von Willebrand factor. Thromb Haemost 93(5):889\u2013896. doi: 10.1267\/THRO05050889","journal-title":"Thromb Haemost"}],"container-title":["Annals of Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2650-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00277-016-2650-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00277-016-2650-x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,15]],"date-time":"2024-06-15T13:01:55Z","timestamp":1718456515000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00277-016-2650-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,4,4]]},"references-count":34,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2016,5]]}},"alternative-id":["2650"],"URL":"https:\/\/doi.org\/10.1007\/s00277-016-2650-x","relation":{},"ISSN":["0939-5555","1432-0584"],"issn-type":[{"value":"0939-5555","type":"print"},{"value":"1432-0584","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,4,4]]}}}